Actualización Guía de Práctica Clínica PANCCO para el tratamiento de la colitis ulcerativa en adultos
Year: 2026
Type: article
Abstract: To update the recommendations of the Pan American Crohn's and Colitis Organisation (PANCCO) for the treatment of moderate-to-severe ulcerative colitis (UC) in adults, incorporating recent evidence on new biologics, small molecules, subcutaneous formulations and appendectomy. The PAHO rapid GRADE methods were applied. PANCCO adapted the Colombian guideline 2025 for upadacitinib, tofacitinib, ozanimod and the switch to subcutaneous formulations, and developed de novo recommendations for etrasimod, guselkumab, risankizumab, ustekinumab, mirikizumab, filgotinib and appendectomy. The search was carried out in MEDLINE, Embase, Cochrane and Epistemonikos through February 2026, with quality appraised with ROBIS, AMSTAR-2, RoB 2.0 and ICEMAN; strength of recommendations was established using GRADE. Recommendations were issued for nine clinical questions. In moderate-to-severe UC, upadacitinib, tofacitinib, filgotinib, ustekinumab, mirikizumab, risankizumab and guselkumab are recommended; ozanimod and etrasimod are conditionally suggested, considering the cardiovascular profile. In patients with response to intravenous induction, switching to subcutaneous vedolizumab or subcutaneous infliximab is suggested. In UC refractory to advanced therapies, laparoscopic appendectomy is conditionally suggested as an adjuvant strategy. This third update expands the therapeutic armamentarium for moderate-to-severe UC in Latin America. Treatment choice should be individualized according to prior therapy, comorbidities, cardiovascular and thrombotic risk, availability and patient preferences.
Authors: Paulina Núñez Figueroa, Abel Sánchez Orozco, Ignacio Alfaro Pérez, María Teresa Andara Ramírez, Domingo Balderramo, Sócrates Bautista, Federico Cassella, Luis Alberto Cervera Caballero, Jorge Luis De León Rendón, Juan De Lucas Ocaña, Eduardo García Vilela, Maria Luisa Jara Alba, Melvin Linares Serrano, Manuel Alejandro Martínez-Vázquez, Sergio Daniel Morínigo Bogado, Ruben Muñoz Camacho, Viviana Parra-Izquierdo, Johana Pérez Baldíoceda, Fabián Eduardo Puentes-Manosalva, Ximena Rodríguez Olaso, Rogério Saad-Hossne, Mariastella Serrano, Miosotis Suarez, Elizabeth Umaña Solis, Rodrigo Pardo-Turriago, Sandra Yuseff, Tatiana Lozano, Fabián Juliao-Baños
Institutions: Universidad de Los Andes, Chile, Hospital San Juan de Dios, University of Chile, Universidad de San Carlos de Guatemala, Roosevelt Hospital, University of Concepción, Hospital Regional de Concepción, Hospital Privado, Instituto Universitario de Ciencias Biomédicas de Córdoba, Hospital Nacional Edgardo Rebagliati Martins, Hospital General de México, Saint Thomas Hospital, Universidade Federal de Minas Gerais, Hospital das Clínicas da Universidade Federal de Minas Gerais, Hospital Zambrano Hellion, Universidad El Bosque, Fundación Cardiovascular de Colombia, Hospital Maciel, Universidade Estadual Paulista (Unesp), Georgetown University, Costa Rican Department of Social Security, Universidad Nacional de Colombia, Hospital Pablo Tobon Uribe
Language: Spanish
Topic: Inflammatory Bowel Disease
Subfield: Gastroenterology
Field: Medicine
Domain: Health Sciences
Keywords: ulcerative colitis, moderate-to-severe ulcerative colitis, biologic therapy, small molecule therapy, upadacitinib, tofacitinib, filgotinib, ustekinumab, mirikizumab, risankizumab, guselkumab, vedolizumab, infliximab, subcutaneous formulation, appendectomy, treatment guidelines, Latin America
Open Access status: diamond
OpenAlex ID: W7167692406
